Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

NCT02695459 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Carcinomas

Interventions

DRUG: cisplatinum and everolimus

Sponsor

The Netherlands Cancer Institute